Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07645248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 15 → 18 locations
  2. Recruitment opened
    • Trial sites expanded: 0 → 15 locations
    • Start date changed from estimate of Sep 15, 2026 to Sep 1, 2026
    • Eligibility criteria expanded, about 27 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Asthma
956 trials monitored
See 34 trials at risk
This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).
Trial Details
NCT Number NCT07645248
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Asthma
Related terms Asthma, Bronchial Spasm
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov